Engineered immunotherapy drug eliminates aggressive metastatic cancers in clinical trial
The researchers demonstrate that an engineered antibody improves a class of drugs that has struggled to make good on its early promise.
Read the full articleYou might also wanna read
FDA-approved drug may finally help immunotherapy defeat rare liver cancer
Researchers found that a rare liver cancer evades immunotherapy by luring immune T cells away from the tumor and trapping them in nearby fib
Experimental mRNA cancer vaccine shows tumor-fighting promise in mouse study
A breakthrough mRNA cancer vaccine has shown the ability to supercharge the effects of immunotherapy in mice, sparking hope for a universal
Immunotherapy shows long-term promise in aggressive lymphoma
A leading-edge immunotherapy may extend survival for patients with one of the most aggressive forms of blood cancer, according to newly publ
Immunotherapy Shows Long-Term Promise in Aggressive Lymphoma
A leading-edge immunotherapy may extend survival for patients with one of the most aggressive forms of blood cancer, according to newly publ
Mapping the TCR landscape: computational tools empowering translational immunology and therapy design
Introduction Cancer immunotherapy harnesses the body’s own immune system to eliminate malignant cells by enhancing or redirecting the immune
jitc.bmj.com·24d agoUmoja Receives FDA IND Clearance for CD22-Directed In Vivo CAR-T Therapy
July 16, 2026 — Umoja Biopharma announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application fo
Comments
Sign in to join the conversation.
No comments yet. Be the first.